Skip to content

Clinical Evaluation and Standardization Study on Treatment of Chronic Soft Tissue Injury with Ma-sang-gou-bang oil of Miao medicine Scraping Method

Clinical Evaluation and Standardization Study on Treatment of Chronic Soft Tissue Injury with Ma-sang-gou-bang oil of Miao medicine Scraping Method

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17013027
Enrollment
Unknown
Registered
2017-10-18
Start date
2015-12-28
Completion date
Unknown
Last updated
2017-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Soft Tissue Injury

Interventions

The control group :Pure tea oil scraping therapy
Group 1:0.38g/m concentration of Ma-sang-gou-bang oil scraping therapy
Group 2:0.77g/ml concentration of Ma-sang-gou-bang oil scraping therapy
Group 3:1.54g/m concentration of Ma-sang-gou-bang oil scraping therapy

Sponsors

The first affiliated hospital of guiyang college of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
17 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) the diagnostic criteria of western medicine and miao medical treatment for the diagnosis of seedling in the case of chronic soft tissue injury; (2) the lesion of the soft tissue is in the lower back, and the duration is not shorter than one month; the VAS integral is over three points; (3) there was no obvious improvement in at least 2 consecutive weeks of moderate rest or other treatment; (4) Aged 18 ~ 75 years old; (5) volunteer for the test and sign the informed consent form; (6) not receiving any treatment related to the disease within 2 weeks prior to the trial, or receiving other treatment but no relief; (7) no other treatment or fatigue exercisers can be received during the evaluation of this test.

Exclusion criteria

Exclusion criteria: (1) non-conforming to chronic soft tissue injury diagnostic criteria; (2) after imaging examination, local soft tissue pain may be related to the involvement of the herniation of the vertebral canal, herniated disc herniation or bulges, etc.; (3) local patients with non-specific infectious inflammation, tuberculosis and fracture; (4) serious organic disease, such as a cerebral vascular accident, myocardial infarction and serious arrhythmia in half a year; (5) to eliminate the pain caused by peripheral vascular lesions, such as vasculitis, raynaud syndrome, etc.; (6) malignant tumor, collagenous connective tissue disease, hemorrhagic disease, local patients with skin disease, etc.; (7) drug and methodological agents who have been involved in the intervention of other than this test programme during treatment; (8) in compliance with poor compliance, no treatment is required to determine the curative effect. Note: all patients who meet the above mentioned above shall be excluded.

Design outcomes

Primary

MeasureTime frame
Quality of life questionnaire (sf-36);VAS score sheet;Clinical symptoms and signs classification table;

Countries

China

Contacts

Public Contactsunjun

Guiyang college of Traditional Chinese Medicine

458041899@qq.com+86 15185178734

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026